Search Results for keywords:"intellectual property"

The National Institute of Allergy and Infectious Diseases (NIAID) is offering royalty-free access to a specially developed starting material, known as "MVA clone-1," for creating and commercializing a vaccine against mpox. This initiative aims to improve vaccine access, especially in underserved regions, and respond to a 2024 public health emergency called by the World Health Organization due to a significant outbreak in the Democratic Republic of the Congo. Interested parties with solid plans to develop and distribute the vaccine in high-need areas can collaborate with NIAID. The material shows promise as it is similar to an already approved vaccine and has been shown to protect against mpox in both normal and at-risk populations.

The U.S. International Trade Commission has begun an investigation following a complaint filed by Synesqo SA, Solvay Specialty Polymers USA LLC, and Solvay Specialty Polymers Italy S.P.A. The complaint claims that certain companies in China are wrongfully importing and selling polyvinylidene fluoride resins in the United States, infringing on specific patent claims. The plaintiffs are asking for the Commission to issue orders to stop these imports and sales. The investigation aims to determine if these claims are valid and if a relevant U.S. industry is significantly impacted or in development.

The National Cancer Advisory Board will hold a virtual meeting on February 13, 2025, which is open to the public except for a portion that involves confidential discussions about grant applications. The meeting can be accessed online through the NIH Videocast link. It will cover subcommittee meetings, reports, presentations, and board business, with a closed session to evaluate grant applications. Those interested can find more information or submit comments through the contact details provided.

NASA plans to grant an exclusive, co-exclusive, or partially exclusive patent license for a specific invention, a micro non-planar ring oscillator, to AVO Photonics, Inc. This decision is not final, and NASA will consider objections and competitive applications submitted by March 31, 2025. These objections should contain evidence showing that the patent license would not align with federal regulations. For further inquiries, individuals can contact NASA’s Agency Counsel for Intellectual Property.

In a recent notice, the Office of the United States Trade Representative (USTR) announced changes to actions related to a Section 301 investigation concerning China's technology transfer and intellectual property practices. These changes include raising tariffs on certain tungsten, polysilicon, and wafer products from China starting January 1, 2025. The new tariffs, part of President's instructions to encourage China to change its practices, will be 25% for tungsten products and 50% for polysilicon and wafers. This decision considers public feedback, which highlights the potential benefits and risks of these tariff increases.

The National Science Foundation (NSF) has announced an extension for public comments on its proposed intellectual property policy, giving interested parties until February 21, 2025, to respond. These proposals aim to establish flexible intellectual property options for NSF-backed public-private partnerships, ensuring a balanced distribution of intellectual property rights between academic and industrial collaborators. The NSF's proposed options, including licenses for research and commercial use, are designed to foster innovation while adhering to existing federal laws like the Bayh-Dole Act. Stakeholders are invited to provide feedback on issues such as the potential impacts on innovation, balance and flexibility in rights distribution, and barriers to adoption.

The Department of the Air Force has announced its intention to grant a partially exclusive patent license to Polaris Sensor Technologies, Inc. for a pioneering invention in imaging technology. The patent involves a new design of microgrid imaging polarimeters that enhance image quality and resolution. Interested parties have 15 days from the publication date to file objections if they believe the license does not comply with regulations. Additional details and procedures for objections are provided, and alternative applications can be considered as valid objections if properly completed and timely submitted.

The U.S. International Trade Commission reviewed an investigation regarding the importation and sale of certain photovoltaic connectors, which allegedly infringed on specific patent claims. Initially, there was a finding of a violation of section 337 of the Tariff Act concerning the '153 patent. However, upon review, the Commission reversed this finding, determining that there was no violation due to the accused products not satisfying the necessary patent claims. The investigation has been concluded with no violation found.

The National Institutes of Health (NIH) is offering a government-owned invention for licensing. This invention is a vaccine that uses a virus vector called VSV-EBOV to express the spike protein of the SARS-CoV-2 virus, which causes COVID-19. The vaccine has shown effective protection against the virus in animal tests, and it only requires a single dose. It is designed to be inexpensive to produce and provides high levels of antibodies to fight COVID-19.

The U.S. International Trade Commission has started a formal enforcement proceeding regarding cease and desist orders issued in an investigation about certain blood flow restriction devices. This action relates to the alleged infringement of U.S. patents and trademarks by two companies, Rhino, Inc. from Delaware and Wuxi Emsrun Technology Co., Ltd. from China. Despite previous orders, these companies are accused of continuing to sell products that violate these protections. The Commission will investigate these allegations and determine if any enforcement measures are needed.